Cargando…

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Edaravone is a low-molecular-weight antioxidant drug targeting peroxyl radicals among many types of reactive oxygen species. Because of its amphiphilicity, it scavenges both lipid- and water-soluble peroxyl radicals by donating an electron to the radical. Thus, it inhibits the oxidation of lipids by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Kazutoshi, Tanaka, Masahiko, Yuki, Satoshi, Hirai, Manabu, Yamamoto, Yorihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	the Society for Free Radical Research Japan 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773834/ https://www.ncbi.nlm.nih.gov/pubmed/29371752 http://dx.doi.org/10.3164/jcbn.17-62

Ejemplares similares

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018)

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021)

Stabilizers of edaravone aqueous solution and their action mechanisms. 2. Glutathione
por: Tanaka, Masahiko, et al.
Publicado: (2017)

Stabilizers of edaravone aqueous solution and their action mechanisms. 1. Sodium bisulfite
por: Tanaka, Masahiko, et al.
Publicado: (2017)

Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
por: Genge, Angela, et al.
Publicado: (2022)

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)

Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients
por: Samadhiya, Swapnil, et al.
Publicado: (2022)

Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023)

Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System
por: Vu, Michelle, et al.
Publicado: (2020)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
por: Han, Hee Jo, et al.
Publicado: (2022)

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
por: Cha, Sun Joo, et al.
Publicado: (2022)

Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis
por: Nourelden, Anas Zakarya, et al.
Publicado: (2023)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Park, Jin-Mo, et al.
Publicado: (2022)

Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite
por: Yamamoto, Yorihiro
Publicado: (2017)

4-Cl-edaravone and (E)-2-chloro-3-[(E)-phenyldiazenyl]-2-butenoic acid are the specific reaction products of edaravone with hypochlorite
por: Amekura, Sakiko, et al.
Publicado: (2020)

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
por: Abe, Koji, et al.
Publicado: (2014)

Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
por: Ortiz, Juan Fernando, et al.
Publicado: (2020)

In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis
por: Sadr, Ahmad Shahir, et al.
Publicado: (2021)

Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke
por: Matsumoto, Shohei, et al.
Publicado: (2018)

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
por: Shefner, Jeremy, et al.
Publicado: (2019)

Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial
por: Eishi-Oskouei, Alireza, et al.
Publicado: (2021)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
por: Houzen, Hideki, et al.
Publicado: (2021)

Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study
por: Shi, Fenghao, et al.
Publicado: (2022)

Amyotrophic lateral sclerosis
por: Wijesekera, Lokesh C, et al.
Publicado: (2009)

Effects of Edaravone on Muscle Atrophy and Locomotor Function in Patients with Ischemic Stroke: A Randomized Controlled Pilot Study
por: Naritomi, Hiroaki, et al.
Publicado: (2012)

Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke
por: Qian, Yun, et al.
Publicado: (2019)

Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19
por: Brooks, Benjamin Rix, et al.
Publicado: (2021)

Amyotrophic lateral sclerosis and neuroregeneration
Publicado: (2012)

Mimickers of Amyotrophic Lateral Sclerosis
por: Dubey, Ayush, et al.
Publicado: (2019)

Destination Amyotrophic Lateral Sclerosis
por: Keon, Matt, et al.
Publicado: (2021)

Prionoids in amyotrophic lateral sclerosis
por: Gosset, Philippe, et al.
Publicado: (2022)

Amyotrophic lateral sclerosis and cerebellum
por: Kabiljo, Renata, et al.
Publicado: (2022)

Dysautonomia in Amyotrophic Lateral Sclerosis
por: Oprisan, Alexandra L., et al.
Publicado: (2023)

Descriptive Epidemiology of Amyotrophic Lateral Sclerosis in Japan, 1995-2001
por: Okamoto, Kazushi, et al.
Publicado: (2005)

Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis
por: Yamashita, Satoshi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r4q4j4auso6g6oi64e8tgq2oje